MX2022011167A - Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana. - Google Patents

Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana.

Info

Publication number
MX2022011167A
MX2022011167A MX2022011167A MX2022011167A MX2022011167A MX 2022011167 A MX2022011167 A MX 2022011167A MX 2022011167 A MX2022011167 A MX 2022011167A MX 2022011167 A MX2022011167 A MX 2022011167A MX 2022011167 A MX2022011167 A MX 2022011167A
Authority
MX
Mexico
Prior art keywords
pathogens
innate immune
detection
human milk
methods
Prior art date
Application number
MX2022011167A
Other languages
English (en)
Inventor
Rachael Buck
Steven Davis
Geralyn Duska-Mcewen
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2022011167A publication Critical patent/MX2022011167A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52Adding ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30Dietetic or nutritional methods, e.g. for losing weight
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se divulga un método para mejorar la respuesta inmune innata de la mucosa de un individuo a los patógenos. El método incluye una etapa de administración de una composición nutricional al individuo. La composición nutricional incluye de cerca de 0.05 a cerca de 0.5 mg/mL de fucosillactosa-2' (2 '-FL), de cerca de 0.05 a cerca de 0.5 mg/mL de lacto-N neotetraosa (LNnT), o una combinación de ambos. También se divulga un método para mejorar la detección inmune innata de la mucosa del individuo de patógenos. El método incluye una etapa de administración una composición nutricional al individuo. La composición nutricional incluye un oligosacárido neutro de la leche humana.
MX2022011167A 2014-04-08 2016-10-05 Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana. MX2022011167A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461976791P 2014-04-08 2014-04-08

Publications (1)

Publication Number Publication Date
MX2022011167A true MX2022011167A (es) 2022-10-18

Family

ID=52988462

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016013064A MX2016013064A (es) 2014-04-08 2015-04-03 Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana.
MX2022011167A MX2022011167A (es) 2014-04-08 2016-10-05 Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016013064A MX2016013064A (es) 2014-04-08 2015-04-03 Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana.

Country Status (10)

Country Link
US (1) US10792294B2 (es)
EP (2) EP3129030A1 (es)
CN (2) CN106132420A (es)
CA (2) CA2942732C (es)
HK (1) HK1231398A1 (es)
IL (1) IL247465B (es)
MX (2) MX2016013064A (es)
PH (1) PH12016501974A1 (es)
SG (1) SG11201608248YA (es)
WO (1) WO2015157098A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040050B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
EP3212197A4 (en) * 2014-10-29 2018-07-11 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome
US11040049B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
AU2016227600B2 (en) 2015-03-05 2020-05-21 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children
WO2016138911A1 (en) * 2015-03-05 2016-09-09 Glycom A/S Composition and method for treating acute respiratory tract infections
WO2017071716A1 (en) 2015-10-28 2017-05-04 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
WO2017071715A1 (en) 2015-10-28 2017-05-04 Glycom A/S Synthetic composition and method for modulating brain function and behaviour
WO2017084673A1 (en) * 2015-11-17 2017-05-26 Glycom A/S Synthetic Composition for Treating Antibiotic Associated Complications
DK3452050T3 (da) * 2016-05-05 2023-02-20 Glycom As Composition comprising hmos for the treatment of noninfectious diarrhoea
EP3458073B1 (en) * 2016-05-19 2023-10-25 Glycom A/S Use of human milk oligosaccharides for treating migraine in patients with inflammatory bowel syndrome
WO2017215722A1 (en) * 2016-06-15 2017-12-21 Glycom A/S Synthetic composition comprising hmo and method for modulating emotion and mood disorders
WO2020245311A2 (en) 2019-06-04 2020-12-10 N.V. Nutricia Nutritional composition comprising 2'fucosyllactose and dietary butyrate

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841543B1 (en) 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
NZ337039A (en) 1997-02-21 2001-06-29 Univ Tennessee Res Corp Use of polyunsaturated fatty acids for reducing the incidence of necrotizing entercolitis
US6045854A (en) 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
EP1062873A1 (en) 1999-12-13 2000-12-27 N.V. Nutricia Improved infant formula, protein hydrolysate for use in such an infant formula, and method for producing such a hydrolysate
US6365218B1 (en) 2000-02-04 2002-04-02 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
US6811801B2 (en) 2001-12-12 2004-11-02 Abbott Laboratories Methods and compositions for brightening the color of thermally processed nutritionals
EP2497478A3 (en) 2003-12-05 2012-11-07 Children's Hospital Medical Center Oligosaccaride compositions and use thereof in the treatment of infection
CN101420966B (zh) * 2006-03-10 2013-07-17 纽崔西亚公司 不可消化的糖用于在出生后给予婴儿最佳开始的用途
US8197872B2 (en) 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
CA2705014A1 (en) * 2007-11-08 2009-05-14 Nestec S.A. Use of oligosaccharides containing n-acetyllactosamine for maturation of immune responses in neonates
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
EP2451462B1 (en) 2009-07-06 2017-09-06 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US20120177691A1 (en) 2009-07-15 2012-07-12 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
US20120178674A1 (en) * 2009-07-15 2012-07-12 N.V. Nutricia Mixture of non-digestible oligosaccharides for stimulating the immune system
WO2011119023A1 (en) 2010-03-26 2011-09-29 N.V. Nutricia Low protein infant formula with increased essential amino acids
EP2455387A1 (en) 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2454948A1 (en) 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2465507A1 (en) 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating skin diseases
EP2465508A1 (en) 2010-11-23 2012-06-20 Nestec S.A. Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
EP2658548B1 (en) 2010-12-31 2018-02-21 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
WO2012092155A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
SG10202110501RA (en) 2010-12-31 2021-11-29 Abbott Lab Methods For Decreasing The Incidence Of Necrotizing Enterocolitis In Infants, Toddlers, Or Children Using Human Milk Oligosaccharides
SG191395A1 (en) 2010-12-31 2013-08-30 Abbott Lab Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
CN103402376A (zh) * 2010-12-31 2013-11-20 雅培制药有限公司 促进有益细菌生长的中性人乳寡糖
MX352040B (es) * 2010-12-31 2017-11-07 Abbott Lab Formulaciones nutricionales que incluyen los oligosacaridos de leche humana y los acidos grasos poliinsaturados de cadena larga y usos de las mismas.
NZ613180A (en) 2010-12-31 2015-02-27 Abbott Lab Methods of using human milk oligosaccharides for improving airway respiratory health
MY180910A (en) 2010-12-31 2020-12-11 Abbott Lab Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
CA2824960A1 (en) 2011-02-04 2012-08-09 The Regents Of The University Of California Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
MY161034A (en) 2011-02-10 2017-04-14 Nestec Sa Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
WO2012158517A1 (en) 2011-05-13 2012-11-22 Glycosyn LLC The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
US20130012472A1 (en) * 2011-07-05 2013-01-10 Boston College Composition and methods of inhibiting gastrointestinal pathogen infection
US10639319B2 (en) * 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract

Also Published As

Publication number Publication date
US20170020906A1 (en) 2017-01-26
HK1231398A1 (zh) 2017-12-22
EP3673909A1 (en) 2020-07-01
CA3179163A1 (en) 2015-10-15
IL247465B (en) 2020-11-30
CA2942732C (en) 2023-01-03
CN113331426A (zh) 2021-09-03
EP3129030A1 (en) 2017-02-15
SG11201608248YA (en) 2016-10-28
IL247465A0 (en) 2016-11-30
CN106132420A (zh) 2016-11-16
CA2942732A1 (en) 2015-10-15
WO2015157098A1 (en) 2015-10-15
US10792294B2 (en) 2020-10-06
PH12016501974A1 (en) 2016-12-19
MX2016013064A (es) 2017-01-26

Similar Documents

Publication Publication Date Title
MX2022011167A (es) Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana.
PH12018501221A1 (en) Mixture of hmos
PH12021550318A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EA201792547A1 (ru) Популяции бактерий для стимуляции состояния здоровья
WO2016033439A3 (en) Compositions and methods for the treating an inflammatory disease or disorder
MY187609A (en) Human milk oligosaccharides to ameliorate symptoms of stress
MX2022011742A (es) Composicion nutritiva para el entorno gastrointestinal para proporcionar microbioma y perfil metabolico mejorados.
MY166946A (en) Methods of using human milk oligosaccharides for improving airway respiratory health
PH12017502181A1 (en) Nutritional compositions containing an elevated level of inositol and uses thereof
MY193660A (en) Optimized nutrient food
MX2021013109A (es) Proceso de preparacion de una vacuna tetravalente atenuada contra el virus del dengue.
PH12019500799A1 (en) Personalized pediatric nutrition products comprising human milk oligosaccharides
PH12016501879A1 (en) Immunological composition containing attenuated histophilus somni
PH12018500993A1 (en) Nutritional compositions comprising lactobacillus rhamnosus gg, as well as dietary butyrate and/or a compound for stimulating formation of endogenous butyrate
MX2016014346A (es) Tratamiento de enfermedad de crohn con 6-mercaptopurina de liberacion prolongada.
MX2015012548A (es) Metodos para estimular la maduracion de pulmones e intestinos infantiles.
PH12019500092A1 (en) Nutritional compositions for infants and/or young children comprising oligosaccharides
WO2015159155A3 (en) Novel ademetionine formulations
MY175269A (en) Single high dose of mva induces a protective immune response in neonates and infants
PH12014501782A1 (en) Maternal supplement to enhance immune system of an infant
Mekinian Severe neutropenia: case report
Sangrador Pelluz Non-immediate hypersensitivity reaction, managed with desensitisation: case report
UA64817U (ru) Способ лечения больных синдромом повышенной усталости с использованием апипрепаратов